Drug Trial Radar · NCT01914393
Pediatric Open-Label Extension Study
Last checked: Nov 20, 2026Latest source record: Dec 19, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
702
Actual
Start
Sep 30, 2013
Primary completion
Oct 17, 2018
Study completion Oct 17, 2018
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 2, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have completed the 6-week treatment period in the preceding studies, D1050301, D1050325, and D1050326
Conditions
- Schizophrenia
- Autism
- Bipolar Depression
Interventions
Lurasidone 20, 40, 60, 80 mg, flexibly dosedDrug
Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Adverse Events (AEs), Discontinuations Due to AEs and Serious AEs (SAEs)Time frame: During 104 Weeks (2-years) treatment period
Locations
88 sites in 15 countries. Site status is shown where the registry gives one.
Harmonex Neuroscience Research
Dothan, Alabama
Diligent Clinical Trials, Inc
Downey, California
University of California San Francisco Medical Center
San Francisco, California
Neuropsychiatric Research Center of Orange County
Santa Ana, California
Sarkis Clinical Trials - Parent
Gainesville, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
APG Research, LLC
Orlando, Florida
Medical Research Group of Central Florida
Sanford, Florida
University of South Florida
St. Petersburg, Florida
University of South Florida Rothman Center of Neuropychiatry
Tampa, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
Attalla Consultants, LLC
Smyrna, Georgia
Psychiatric Associates
Overland Park, Kansas
University Of Kentucky
Lexington, Kentucky
Lake Charles Clinical Trials LLC,2770 3rd Avenue,Suite 340
Lake Charles, Louisiana
Kennedy Krieger Institute
Baltimore, Maryland
Neurobehavioral medicine Group, LLC
Bloomfield Hills, Michigan
St. Charles Psychiatric Associates
Saint Charles, Missouri
Jersey Shore University Medical Center
Neptune City, New Jersey
North Shore/Long Island Jewish PRIME
Glen Oaks, New York
Dr. Jeanette Cueva
Mount Kisco, New York
Montefiore Medical Center PRIME
New York, New York
Finger Lakes Clinical Research
Rochester, New York
Richmond Behavioral Associates
Staten Island, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
University Hospitals Case Medical Center
Cleveland, Ohio
The Ohio State University Nisonger Center
Columbus, Ohio
Cutting Edge Research Group
Oklahoma City, Oklahoma
Pillar Clinical Research, LLC
Dallas, Texas
Family Psychiatry of The Woodlands, P.A.
The Woodlands, Texas
Ericksen Research & Development, LLC
Clinton, Utah
University of Virginia
Charlottesville, Virginia
Neuroscience, Inc.
Herndon, Virginia
Clinical Research Partners, LLC
Petersburg, Virginia
Carilion Clinic
Roanoke, Virginia
MHC - Ruse, EOOD
Rousse, Bulgaria
UMHAT "Alexandrovska" EAD
Sofia, Bulgaria
MHAT-Targovishte, AD
Targovishte, Bulgaria
DCC "Mladost M" - Varna, OOD
Varna, Bulgaria
Centro de Investigaciones y Proyectos en Neurociencias CIPNA
Barranquilla, Colombia
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.